U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Bivalirudin is a synthetic 20 amino acid peptide rationally designed based on structural studies of hirudin, a naturally occurring anticoagulant. Bivalirudin is sold under the brand name Angiomax and is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). It is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. Bivalirudin directly inhibits thrombin by binding simultaneously to its active catalytic site and its substrate recognition site.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P00734|||Q9UCA1
Gene ID: 2147.0
Gene Symbol: F2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ANGIOMAX

Approved Use

Angiomax™ is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Angiomax is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Launch Date

9.7683839E11
PubMed

PubMed

TitleDatePubMed
Thrombin-specific inhibition by and slow cleavage of hirulog-1.
1992 May 1
Development and current applications of thrombin-specific inhibitors.
2001 Jun
Bivalirudin: a new approach to anticoagulation.
2001 Mar-Apr
Current developments in antithrombotic therapy: the role of antithrombin agents.
2002
Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction.
2002
Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
2002
Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.
2002 Apr
New drugs 2002. Part II.
2002 Apr
Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.
2002 Apr
Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures.
2002 Aug
Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplasty.
2002 Aug
Direct thrombin inhibitors in acute coronary syndromes.
2002 Aug 10
Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery.
2002 Dec
Current anticoagulation options in percutaneous intervention: designing patient-specific strategies.
2002 Fall
Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction.
2002 Feb
Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.
2002 Jun
The role of thrombin inhibition during percutaneous coronary intervention.
2002 Jun
A practical cost analysis of bivalirudin.
2002 Jun
Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions.
2002 Jun
Absolute and relative truth in clinical trials.
2002 Jun 1
Reversing anticoagulants both old and new.
2002 Jun-Jul
Percutaneous coronary intervention with bivalirudin anticoagulation, immediate sheath removal, and early ambulation: a feasibility study with implications for day-stay procedures.
2002 Mar
[What is new in antithrombotic treatment?].
2002 Mar-Apr
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
2002 May
Gateways to clinical trials.
2002 Oct
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion.
2002 Sep
Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
2003
Direct thrombin inhibitors in cardiac disease.
2003
Management of thrombotic and cardiovascular disorders in the new millenium.
2003 Apr
Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?
2003 Aug
Clinician update: direct thrombin inhibitors in acute coronary syndromes.
2003 Feb
The evolving role of direct thrombin inhibitors in acute coronary syndromes.
2003 Feb 19
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
2003 Feb 19
Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia.
2003 Jan-Feb
Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits.
2003 Jul
Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia [corrected].
2003 Jul
Bivalirudin in peripheral vascular interventions: a single center experience.
2003 Jul
Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study.
2003 Jun
Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure.
2003 Mar
Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study.
2003 Mar 15
Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.
2003 Mar 15
Predicting the pharmacology of thrombin inhibitors.
2003 May
Direct thrombin inhibitors.
2003 May
Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations.
2003 May 1
A 24-hour continuous infusion study of bivalirudin in the rat.
2003 May-Jun
Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention.
2003 Nov 1
Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia.
2003 Oct
Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
2003 Oct
Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials.
2003 Oct 15
Bivalirudin in percutaneous coronary intervention.
2003 Sep 15
Patents

Sample Use Guides

The recommended dosage of Angiomax (bivalirudin) is an intravenous (IV) bolus dose of 1.0 mg/kg followed by a 4-hour IV infusion at a rate of 2.5 mg/kg/h. After completion of the initial 4-hour infusion, an additional IV infusion of Angiomax may be initiated at a rate of 0.2 mg/kg/h for up to 20 hours if needed.
Route of Administration: Intravenous
Substance Class Protein
Created
by admin
on Sun Dec 18 19:34:36 UTC 2022
Edited
by admin
on Sun Dec 18 19:34:36 UTC 2022
Protein Sub Type
Sequence Type COMPLETE
Record UNII
TN9BEX005G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BIVALIRUDIN
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
bivalirudin [INN]
Common Name English
BIVALIRUDIN [ORANGE BOOK]
Common Name English
BIVALIRUDIN [VANDF]
Common Name English
BIVALIRUDIN [MART.]
Common Name English
Bivalirudin [WHO-DD]
Common Name English
BIVALIRUDIN [EMA EPAR]
Common Name English
BG-8967
Code English
L-LEUCINE, D-PHENYLALANYL-L-PROLYL-L-ARGINYL-L-PROLYLGLYCYLGLYCYLGLYCYLGLYCYL-L-ASPARAGINYLGLYCYL-L-.ALPHA.-ASPARTYL-L-PHENYLALANYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-ISOLEUCYL-L-PROLYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-TYROSYL-
Systematic Name English
BIVALIRUDIN [MI]
Common Name English
BIVALIRUDIN [USP-RS]
Common Name English
BG8967
Code English
BIVALIRUDIN [USAN]
Common Name English
Classification Tree Code System Code
WHO-ATC B01AE06
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
FDA ORPHAN DRUG 200204
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
NDF-RT N0000175980
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
NDF-RT N0000175518
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
NCI_THESAURUS C263
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
Code System Code Type Description
DAILYMED
TN9BEX005G
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
RS_ITEM_NUM
1076013
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
EVMPD
SUB05862MIG
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
DRUG CENTRAL
385
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
MERCK INDEX
M2581
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
DRUG BANK
DB00006
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
CAS
128270-60-0
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
USAN
FF-67
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
CHEBI
59173
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
NCI_THESAURUS
C47415
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
FDA UNII
TN9BEX005G
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
WIKIPEDIA
Bivalirudin
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
EPA CompTox
DTXSID00155847
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
INN
7282
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
LACTMED
Bivalirudin
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
RXCUI
60819
Created by admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC